FLGT

Fulgent Genetics

• TipRanks·5d ago

  Fulgent Genetics Highlights Promising FID-007 Phase 2 Results

• Benzinga·5d ago

  Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile

• PUBT·5d ago

  Fulgent posts Phase 2 data: FID-007 plus cetuximab shows 60% ORR in HNSCC

• Reuters·5d ago

  FULGENT ANNOUNCES RAPID ORAL FULL ABSTRACT PUBLICATION FOR FID-007 WITHIN THE HEAD AND NECK CANCER TRACK SESSION AT THE ASCO 2026 ANNUAL MEETING

• TipRanks·05/14 21:45

  Fulgent Genetics Shareholders Approve New 2026 Equity Plan

• Dow Jones·05/05 18:21

  Fulgent Genetics Price Target Cut to $15.00/Share From $30.00 by Piper Sandler

• Benzinga·05/05 18:11

  Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15

• TipRanks·05/05 11:00

  Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler

• Reuters·05/05 07:07

  U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi

• Reuters·05/05 03:12

  FULGENT GENETICS INC <FLGT.O>: PIPER SANDLER CUTS TARGET PRICE TO $15 FROM $30

• TipRanks·05/04 11:06

  Foundation Medicine to launch FoundationOnePGx through partnership with Fulgent

• TipRanks·05/02 00:34

  Fulgent Genetics Bets On H2 Rebound After Tough Q1

• Press release·05/01 20:01

  Fulgent Genetics, Inc. Reports Financial Results for the Quarter Ended March 31, 2026

• Seeking Alpha·05/01 16:23

  Fulgent outlines $350M 2026 revenue outlook following Bako/StrataDx acquisition

• TipRanks·05/01 14:57

  Fulgent Genetics Posts Q1 Loss, Reaffirms 2026 Outlook